Skye Bioscience, Inc. SKYE 深 滬
等待開盤 09-09 09:30:00 美东时间
4.12
+0.120
+3.00%
華盛通- 最 高4.21
- 今 開4.07
- 成交量 41.24万股
- 最 低 3.8313
- 昨 收 4.00
- 總市值 1.28亿
- 52周最高 6.13
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.14
- 委 比 2.91%
- 總股本 3098.84万
- 歷史最高 17.6473
- 量 比 1.24
- 振 幅 9.47%
- 歷史最低 1.14
- 每 手 1
- 風險率 3.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Skye's Nimacimab Boosts Tirzepatide Results And Helps Maintain Weight Loss In Mouse Studies
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today reported results from two new
09-04 19:10
Skye’s CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model
Skye Bioscience reported promising preclinical data for nimacimab, a peripheral CB1-inhibiting antibody, showing over 40% weight loss when combined with tirzepatide, superior post-treatment weight maintenance vs monlunabant, and reduced rebound weight gain. Nimacimab is positioned as a potential standalone, combination, and maintenance therapy for obesity, with Phase 2 results expected in late 2025.
09-04 11:00
Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study
Skye Bioscience has completed the 26-week primary endpoint of its Phase 2a CBeyond™ trial evaluating nimacimab, a peripheral CB1 inhibitor antibody, for obesity and overweight. The trial also includes a 26-week extension to assess 52-week data with a 13-week follow-up. Key points: nimacimab's potential as a monotherapy or in combination with semaglutide; focus on addressing limitations of GLP-1 drugs; and plans to report data from the extension i...
09-02 11:00
Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout
Skye Bioscience will host a virtual KOL event on September 4, 2025, at 8:00 AM ET, discussing upcoming Phase 2a CBeyond trial results of nimacimab, a peripheral CB1 antibody for obesity. The event, featuring key opinion leaders, will cover study success criteria, mechanism insights, new preclinical data, and a Q&A session. Registration is required for participation.
08-27 11:00
Skye Bioscience to Participate in Upcoming Investment and Medical Conferences
Skye Bioscience将参与多个投资和医疗会议，包括Cantor Global Healthcare Conference、H.C. Wainwright Global Investment Conference、Morgan Stanley Global Healthcare Conference及Obesity Science & Innovation和EASD会议，重点讨论肥胖治疗和代谢疾病。公司专注于开发基于G蛋白偶联受体的创新疗法，正在开展IIa期临床试验评估其药物nimacimab的安全性和疗效。如需更多信息，请访问公司官网。
08-21 11:00
美股大行评级 | Macquarie维持小鹏汽车"跑赢大市"评级，目标价升至25美元
今日重点评级关注：HC Wainwright & Co.：维持BioXcel Therapeutics"买入"评级，目标价从8美元升至10美元；Craig-Hallum：维持Fennec Pharmaceuticals"买入"评级，目标价从13美元升至14美元
08-18 10:22
Evercore ISI Group Initiates Coverage On Skye Bioscience with Outperform Rating, Announces Price Target of $10
Evercore ISI Group analyst Michael DiFiore initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Outperform rating and announces Price Target of $10.
08-16 01:52
Skye initiated at overweight at Evercore on obesity asset nimacimab
Evercore ISI is bullish on the prospects for Skye Bioscience (NASDAQ:SKYE) due to its development of the CB1 inhibitor nimacimab for obesity. The firm has a $10 price target (~206% upside based on Thu...
08-15 21:43
Skye Bioscience Q2 EPS $(0.44) Misses $(0.31) Estimate
Skye Bioscience (NASDAQ:SKYE) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.31) by 40.58 percent. This is a 120 percent decrease over losses of $(0.20) per share from
08-08 04:45
Here are the major earnings after the close Thursday
Major earnings expected after the bell on Thursday include: Block (XYZ) Gilead Sciences (GILD) Twilio (TWLO) The Trade Desk (TTD) Main Street Capital Corporation (MAIN) Other earnings slated for rele...
08-07 22:00
